Brigatinib versus crizotinib for ALK-positive NSCLC

MeSH terms

• Anaplastic Lymphoma Kinase / antagonists & inhibitors*
• Anaplastic Lymphoma Kinase / genetics
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use*
• Carcinoma, Non-Small-Cell Lung / drug therapy*
• Carcinoma, Non-Small-Cell Lung / enzymology
• Carcinoma, Non-Small-Cell Lung / genetics
• Carcinoma, Non-Small-Cell Lung / mortality
• Clinical Trials, Phase III as Topic
• Crizotinib / adverse effects
• Crizotinib / therapeutic use*
• Humans
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / enzymology
• Lung Neoplasms / genetics
• Lung Neoplasms / mortality
• Multicenter Studies as Topic
• Organophosphorus Compounds / adverse effects
• Organophosphorus Compounds / therapeutic use*
• Progression-Free Survival
• Protein Kinase Inhibitors / adverse effects
• Protein Kinase Inhibitors / therapeutic use*
• Pyrimidines / adverse effects
• Pyrimidines / therapeutic use*
• Randomized Controlled Trials as Topic
• Time Factors